232 Comparative efficacy and safety of enoxaparin and fondaparinux in non-high risk acute pulmonary embolism: an adjusted propensity score analysis
- Meneveau, Nicolas
- Descotes-Genon, Vincent
- Chopard, Romain
- Séronde, Marie France
- Luporsi, Paul
- Briand, Florent
- Guignier, Alexandre
- Bernard, Yvette
- Schiele, Francois
DOIAbstract
BackgroundGuidelines recommend low molecular weight heparin (LMWH) and fondaparinux (fonda) over unfractionated heparin (UFH) for initial treatment of acute pulmonary embolism (PE), except in patients (pts) at high risk of bleeding & with severe renal dysfunction. No trial has assessed the comparative efficacy of enoxaparin (enox) and fonda in this setting.MethodsProspective, multicenter registry. Pts with proven recent PE (symptom onset <15 days), treated with approved regimens of enox or fonda were included. Pts with high risk PE, and those with recent or active bleeding, recent surgery or stroke, or renal failure were excluded. We calculated a propensity score by logistic regression (i.e. predicted probability of treatment by enox as opp...
Add to ORKG